Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]-FL-261
- Development stage
- Preclinical
- Lead developer
- Full-Life Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]-FL-261 is an investigational radionuclide drug conjugate (RDC) developed by Full-Life Technologies. It consists of the targeting vector FL-261, which exhibits high affinity and selectivity for the c-MET receptor (hepatocyte growth factor receptor), labeled with the alpha-emitting radioisotope Actinium-225 (225Ac). c-MET is a receptor tyrosine kinase frequently overexpressed in various malignancies, including non-small cell lung cancer (NSCLC). The compound is designed as a targeted alpha therapy, leveraging the high linear energy transfer of alpha particles to induce lethal double-strand DNA breaks in tumor cells while minimizing damage to surrounding healthy tissue. Preclinical studies in xenograft mouse models have demonstrated intense and sustained tumor uptake with high specificity confirmed by blocking studies.
- Other names
- 225Ac-FL-261
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on [225Ac]-FL-261.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]-FL-261.